News summary

Fauna Bio designates second obesity target with Lilly

Source: Longevity Technology • Published: 16 Nov 2026, 11:51

Summarized by Masters of Longevity from Longevity Technology.

Fauna Bio and Eli Lilly designated a second obesity target from a different tissue.

Fauna Bio designates second obesity target with Lilly
Key Takeaways
  • Collaboration has produced a second tissue-specific obesity target.
  • Designation has triggered additional milestone payments under the collaboration.
  • Target validation is ongoing and has not established causal efficacy.
Read the full article at Longevity Technology ↗

Continue exploring

Recommended MoL Picks

MoL PickThe Next Obesity-Drug Race Is About What Weight You LoseRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.MoL PickSemaglutide Extended Lifespan in Mice. What Would Make It a Human Longevity Drug?A new animal study sharpens an important question: when do benefits in a particular disease become evidence for a longer, healthier life?MoL PickApoB: The cholesterol signal LDL can missIn longevity medicine, the useful biomarkers are not always the exotic ones. ApoB is a relatively simple blood test that can sharpen cardiovascular prevention when LDL-C looks reassuring but particle burden remains high.